Cell signaling news
Here we present recent news items specially selected from Nature, Nature Medicine and Nature Biotechnology.
July 2003
2003:
December |
November |
October |
September |
August |
July |
June |
May |
April |
March |
February |
January
Other years: 2002 | 2004 | 2005 | 2006 | 2007 | 2008
News | News in brief | News Features
News
Dispute over data privacy halts cancer study
The brakes have been slammed on a major cancer-research project, after the Japan Medical Association (JMA) accused its leaders of failing to provide adequate protection for participants' privacy.
Nature (24 July 2003)
| Full Text |
Brain region linked to post-terror stress
Researchers studying the long-term effects of the 1995 sarin gas attack in the Tokyo underground have unearthed some intriguing clues about what controls different people's susceptibility to the psychological after-effects of shock.
Nature (24 July 2003)
| Full Text |
HIV drug resistance triggers strategic switch
High rates of drug resistance are causing infectious-disease experts to recommend that doctors change the way they use medications against HIV.
Nature (24 July 2003)
| Full Text |
China launches primate centre to broaden medical use of monkeys
Biologists in China plan to capitalize on the region's easy access to primates to set up a global resource for disease research.
Nature (17 July 2003)
| Full Text |
Are China's bioethics under control?
China has similar protocols on biological experimentation to other countries, researchers there often argue, but it is less bureaucratic in implementing them.
Nature (17 July 2003)
| Full Text |
AIDS research cut to pay for anthrax vaccine
The Bush administration is to proceed with plans to skim more than $200 million from research grant programmes to pay for the rapid production of an anthrax vaccine, brushing off the protests of biologists.
Nature (17 July 2003)
| Full Text |
Preliminary inquiry clears brain scientist of fraud allegation
An official investigation has cleared a prominent German neuroscientist of manipulating data in one of two scientific papers under scrutiny.
Nature (17 July 2003)
| Full Text |
Survey reveals mixed feelings over scientific misconduct
Senior scientists in Germany believe that the increased reporting of research misconduct in the media there is damaging public confidence in science, a survey conducted by Nature has found.
Nature (10 July 2003)
| Full Text |
Europe split over move to loosen stem-cell regulations
The European Union (EU) is set to change its rules on embryonic-stem-cell research.
Nature (10 July 2003)
| Full Text |
Drive for patent-free innovation gathers pace
A group of top scientists and economists are asking the World Intellectual Property Organization (WIPO) in Geneva to promote 'open' models of innovation that don't rely on patents.
Nature (10 July 2003)
| Full Text |
DNA-chip firm backs down over upgrade
Biotechnology company Affymetrix is retreating from a plan that would have made it tougher for biologists to use open-source computer software to analyse results from its ubiquitous microarray chips.
Nature (10 July 2003)
| Full Text |
UK shock tactics repel animal-rights activists in Japan
British animal-rights activists have pledged to export their fight to Japan.
Nature (10 July 2003)
| Full Text |
Anger mounts over cutbacks at US army pathology lab
Scientists at a military medical facility in Washington DC have lashed out at plans by the Department of Defense (DOD) to cut back on both its staff and its unique mission.
Nature (3 July 2003)
| Full Text |
Tribunal clears obesity researcher of fraud
A French tribunal has ruled that there are no grounds for the prosecution of Bernard Bihain on charges of 'forgery and use of forgeries'.
Nature (3 July 2003)
| Full Text |
Oxford professor accused of discrimination over e-mail
A pathologist at the University of Oxford is facing an internal inquiry after he refused an Israeli student's PhD application because the student had served in Israel's army.
Nature (3 July 2003)
| Full Text |
Backyard biodefense rouses extreme reactions
Residents of Rome, New York, hosts of the 1999 Woodstock festival, are welcoming a proposal to build a high-security biodefense laboratory on the flower-power festival's former site.
Nature Medicine (July 2003)
| Full Text |
SARS-struck nations step up surveillance efforts
Two weeks after the World Health Organization declared Canada free of SARS, staff members at a Toronto hospital missed warning symptoms in a feverish 96-year-old man. That slip was enough to revive a full-scale SARS outbreak in the city.
Nature Medicine (July 2003)
| Full Text |
China enlists traditional meds for SARS
Experts in traditional Chinese medicine are calling for the use of ancient Chinese remedies in combination with Western treatments to stem SARS.
Nature Medicine (July 2003)
| Full Text |
Europe's new tests let rabbits rest easy
The European Commission is adopting new methods that will spare the lives of nearly 200,000 rabbits each year. Rather than sacrifice rabbits to evaluate intravenous medications, the commission plans to use six in vitro tests that use human blood cells.
Nature Medicine (July 2003)
| Full Text |
Cancer fears stall trials for testosterone replacement
Despite popular demand, trials to evaluate testosterone replacement therapy for men are to remain on hold pending publication of a review by an independent panel of experts.
Nature Medicine (July 2003)
| Full Text |
UK biotech sector loses flagship PowderJect to Chiron
One of Europe's few profitable biotechnology companies, PowderJect, is losing its independence to US rival Chiron in an agreed £542 ($890) million cash deal.
Nature Biotechnology (July 2003)
| Full Text |
Biotech firms jump on SARS bandwagon
Undeterred by the scarcity of clinical data on SARS, several biotechnology and diagnostics firms are joining the global rush to combat the infectious disease.
Nature Biotechnology (July 2003)
| Full Text |
Lawsuits anticipated on generic biologicals front
Late in April, the Biotechnology Industry Organization submitted a citizen's petition to the US Food and Drug Administration, requesting an open public discussion of agency policy regarding "follow-on" biologics — that is, therapeutic proteins and other biotechnology products that may someday be marketed as generic products.
Nature Biotechnology (July 2003)
| Full Text |
Sugen falls as casualty of Pfizer–Pharmacia merger
The first fallout for biotech from the mammoth Pfizer–Pharmacia merger, completed April 16, is the shutdown of Sugen, a pioneering signal transduction company acquired by Pharmacia in 1999.
Nature Biotechnology (July 2003)
| Full Text |
News in brief
Improved SARS test cuts final case count in United States by half
| Women's career award crosses gender divide
| Japanese push for patents 'sidelines basic research'
| Grants plan paves way for Europe-wide funding body
| Academic hopefuls set for pole position in US visa applications
| Oxford don penalized for outburst at Israeli
| Repository to nurture standard stem cells
| Monkeypox makes its debut in the West
| DNA 'Biobank' for African Americans launched
| Studies deliver double blow to Alzheimer disease
| Venter, Duke announce genomic medicine project
| US court limits patents
| EMEA gets fast track
| EU stymies drug importation
| Cephalon scores big
| Japan creates ES cell line
News Features
SARS: What have we learned?
It's less than four months since the World Health Organization issued global warnings about a mysterious and deadly form of pneumonia. Nature's reporters pose key questions about the outbreak, and assess our preparedness to deal with future viral threats.
Nature (10 July 2003)
| Full Text |
Tropical diseases: Raiding the medicine cabinet
Many candidate drugs to fight diseases in the developing world have been shelved before approval — until now. Enter a medical charity that made its name by bringing hope to the world's disaster zones.
Nature (3 July 2003)
| Full Text |
|
